Shi Du
PhD, Distinguished Assistant Professor
International College of Pharmaceutical Innovation
E-mail：dushi0421@gmail.com
Biography
Shi Du is a Distinguished Assistant Professor at the International College of Pharmaceutical Innovation. He received his Bachelor's and Master's degrees in Pharmaceutics from China Pharmaceutical University and earned his Ph.D. in Pharmaceutical Sciences from the College of Pharmacy at the Ohio State University. Before returning to China, he served as a visiting scholar at the Icahn School of Medicine at Mount Sinai in New York and as a postdoctoral researcher in the Department of Biomedical Informatics at the Ohio State University College of Medicine. His research primarily focuses on nucleic acid drug delivery, mRNA therapy, and bioinformatics-assisted drug design. In the past five years, he has published 13 SCI papers as the first author or corresponding author, including Nature Nanotechnology (IF 38.1), Advanced Materials (IF 32), Advanced Science (IF 14.8), and Journal of Controlled Release (IF 10.5). These publications have been cited over 1200 times, with an H-index of 16. He is also a co-inventor on 3 U.S. patent applications and holds 1 authorized domestic patent.
Select Publications (# represents first author, * represents corresponding author)
1. Liu, Y., Qi, Y., Chen, C., Jin, Y., Du, S.*, Qiao, J.*, & Yao, J.* (2023). Platelet-mimetic nano-sensor for combating postoperative recurrence and wound infection of triple-negative breast cancer. Journal of Controlled Release, 362, 396-408.
2. Lv, S., Liu, Y., Xie, C., Xue, C., Du, S.*, & Yao, J.* (2023). Emerging role of interactions between tumor angiogenesis and cancer stem cells. Journal of Controlled Release, 360, 468-481.
3. Zhang, Y.#, Hou, X.#, Du, S.#, Xue, Y., Yan, J., Kang, D. D., ... & Dong, Y. (2023). Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy. Nature Nanotechnology, 18(11), 1364-1374.
4. Du, S. #, Yan, J., Xue, Y., Zhong, Y., & Dong, Y. (2023). Adoptive cell therapy for cancer treatment. Exploration, 3(4), 20210058.
5. Du, S.#, Li, W., Zhang, Y., Xue, Y., Hou, X., Yan, J., ... & Dong, Y. (2023). Cholesterol‐Amino‐Phosphate (CAP) Derived Lipid Nanoparticles for Delivery of Self‐Amplifying RNA and Restoration of Spermatogenesis in Infertile Mice. Advanced science, 10(11), 2300188.
6. Zhong, Y.#, Du, S.#, & Dong, Y. (2023). mRNA delivery in cancer immunotherapy. Acta Pharmaceutica Sinica B, 13(4), 1348-1357.
7. Du, S.#, Cheng, J., & Dong, Y. (2023). Nanomaterials for Therapeutic Nucleic Acid Delivery. Handbook of Chemical Biology of Nucleic Acids (pp. 1-29). Singapore: Springer Nature Singapore.
8. Yan, J.#, Zhang, Y.#, Du, S.#, Hou, X., Li, W., Zeng, C., ... & Dong, Y. (2022). Nanomaterials-mediated co-stimulation of toll-like receptors and CD40 for antitumor immunity. Advanced Materials, 34(47), 2207486.
9. Du, S.#, Xiong, H., & Yao, J. (2021). Redox-Responsive Nanomedicine. Stimuli-Responsive Nanomedicine, 99-132.
10. Chan, C.#, Du, S.#, Dong, Y., & Cheng, X. (2021). Computational and experimental approaches to investigate lipid nanoparticles as drug and gene delivery systems. Current topics in medicinal chemistry, 21(2), 92-114.
11. Du, S.#, Yu, Y., Xu, C., Xiong, H., Yang, S., & Yao, J. (2019). LMWH and its derivatives represent new rational for cancer therapy: construction strategies and combination therapy. Drug discovery today, 24(10), 2096-2104.
12. Du, S.#, Xiong, H., Xu, C., Lu, Y., & Yao, J. (2019). Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines. Biomaterials science, 7(3), 1147-1160.
